36 citations,
May 2011 in “Dermatologic therapy” No treatments fully cure or prevent alopecia areata; some help but have side effects or need more research.
April 2021 in “Research Square (Research Square)” Achieving 80% or more scalp hair regrowth is considered a successful treatment for significant hair loss.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
13 citations,
February 2019 in “Journal of the American Academy of Dermatology” The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
4 citations,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
2 citations,
May 2018 in “Journal of the American Academy of Dermatology” Low vitamin D might be one of several factors involved in the hair loss condition alopecia areata.
December 2021 in “Benha Journal of Applied Sciences” Higher Claudin 3 levels in the blood are linked to more severe alopecia areata.
1 citations,
September 2023 in “Dermatology and Therapy” Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
9 citations,
June 2019 in “Archives of Dermatological Research” Both topical calcipotriol and narrowband UVB improved alopecia, but combining them didn't enhance the effect on hair loss severity, despite higher vitamin D3 levels.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
238 citations,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
222 citations,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
130 citations,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
66 citations,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
42 citations,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
28 citations,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
17 citations,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
12 citations,
January 2011 in “Photodermatology, photoimmunology & photomedicine” This therapy effectively treats resistant alopecia areata with minimal side effects.
11 citations,
May 2021 in “Journal of The American Academy of Dermatology” COVID-19 doesn't make alopecia areata worse.
11 citations,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
11 citations,
December 2018 in “Journal of the European Academy of Dermatology and Venereology” Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
10 citations,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
9 citations,
May 2021 in “International Journal of Dermatology” The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
6 citations,
February 2021 in “Advances in Clinical and Experimental Medicine” Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.
4 citations,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
3 citations,
September 2021 in “Journal of Investigative Dermatology” Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
2 citations,
August 2022 in “JAAD case reports” COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.
2 citations,
May 2022 in “JAAD Case Reports” A woman lost all her hair after mild COVID-19, but it started to regrow after treatment with a specific medication.
1 citations,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
1 citations,
January 2021 in “Journal of clinical and diagnostic research” Using Calcipotriol with Clobetasol is more effective for treating Alopecia Areata than using Clobetasol alone.